Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis
- PMID: 35194860
- PMCID: PMC9969997
- DOI: 10.1111/add.15853
Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis
Abstract
Background and aims: There have been few head-to-head clinical trials of pharmacotherapies for alcohol withdrawal (AW). We, therefore, aimed to evaluate the comparative performance of pharmacotherapies for AW.
Methods: Six databases were searched for randomized clinical trials through November 2021. Trials were included after a blinded review by two independent reviewers. Outcomes included incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from adverse events, length of hospital stay, use of additional medications, total benzodiazepine requirements, and death. Effect sizes were pooled using frequentist random-effects network meta-analysis models to generate summary ORs and Cohen's d standardized mean differences (SMDs).
Results: Across the 149 trials, there were 10 692 participants (76% male, median 43.5 years old). AW severity spanned mild (n = 32), moderate (n = 51), and severe (n = 66). Fixed-schedule chlormethiazole (OR, 0.16; 95% CI, 0.04-0.65), fixed-schedule diazepam (OR, 0.16; 95% CI, 0.04-0.59), fixed-schedule lorazepam (OR = 0.19; 95% CI, 0.08-0.45), fixed-schedule chlordiazepoxide (OR = 0.21; 95% CI, 0.08-0.53), and divalproex (OR = 0.22; 95% CI, 0.05-0.86) were superior to placebo at reducing incident AW seizures. However, only fixed-schedule diazepam (OR, 0.19; 95% CI, 0.05-0.76) reduced incident delirium tremens. Oxcarbazepine (d = -3.69; 95% CI, -6.21 to -1.17), carbamazepine (d = -2.76; 95% CI, -4.13 to -1.40), fixed-schedule oxazepam (d = -2.55; 95% CI, -4.26 to -0.83), and γ-hydroxybutyrate (d = -1.80; 95% CI, -3.35 to -0.26) improved endpoint Clinical Institute Withdrawal Assessment for Alcohol-Revised scores over placebo. Promazine and carbamazepine were the only agents significantly associated with greater dropouts because of adverse events. The quality of evidence was downgraded because of the substantial risk of bias, heterogeneity, inconsistency, and imprecision.
Conclusions: Although some pharmacotherapeutic modalities, particularly benzodiazepines, appear to be safe and efficacious for reducing some measures of alcohol withdrawal, methodological issues and a high risk of bias prevent a consistent estimate of their comparative performance.
Keywords: Alcohol use disorder; comparative effectiveness; meta-analysis; pharmacotherapy; systematic review; withdrawal.
© 2022 Society for the Study of Addiction.
Conflict of interest statement
Declaration of Interests
None
Figures
Similar articles
-
[Assessment of alcohol withdrawal syndrome: new perspectives].Orv Hetil. 2023 Sep 24;164(38):1487-1496. doi: 10.1556/650.2023.32847. Print 2023 Sep 24. Orv Hetil. 2023. PMID: 37742220 Review. Hungarian.
-
Baclofen for alcohol withdrawal.Cochrane Database Syst Rev. 2019 Nov 6;2019(11):CD008502. doi: 10.1002/14651858.CD008502.pub6. Cochrane Database Syst Rev. 2019. PMID: 31689723 Free PMC article.
-
The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review.JBI Database System Rev Implement Rep. 2015 Jan;13(1):224-52. doi: 10.11124/jbisrir-2015-1602. JBI Database System Rev Implement Rep. 2015. PMID: 26447017 Review.
-
The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome.J Clin Pharm Ther. 2010 Apr;35(2):153-67. doi: 10.1111/j.1365-2710.2009.01098.x. J Clin Pharm Ther. 2010. PMID: 20456734 Review.
-
Pharmacotherapies for alcohol abuse. Withdrawal and treatment.Med Clin North Am. 1997 Jul;81(4):881-907. doi: 10.1016/s0025-7125(05)70554-x. Med Clin North Am. 1997. PMID: 9222259 Review.
Cited by
-
ACG Clinical Guideline: Alcohol-Associated Liver Disease.Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. Am J Gastroenterol. 2024. PMID: 38174913
-
Prevalence and clinical impact of alcohol withdrawal syndrome in alcohol-associated hepatitis and the potential role of prophylaxis: a multinational, retrospective cohort study.EClinicalMedicine. 2023 Jun 22;61:102046. doi: 10.1016/j.eclinm.2023.102046. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37415844 Free PMC article.
-
Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management.Eur J Clin Pharmacol. 2023 Sep;79(9):1147-1157. doi: 10.1007/s00228-023-03523-2. Epub 2023 Jun 28. Eur J Clin Pharmacol. 2023. PMID: 37380897 Review.
-
Management of medically assisted withdrawal from alcohol in acute adult mental health and specialist addictions in-patient services: UK clinical audit findings.BJPsych Open. 2023 Apr 11;9(3):e61. doi: 10.1192/bjo.2023.45. BJPsych Open. 2023. PMID: 37038767 Free PMC article.
References
-
- Rahman A, Paul M. Delirium Tremens. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. [cited 2021 Jan 6]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482134/
-
- McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2008; 79(8): 854–62. - PubMed
-
- Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, et al. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism. World J Biol Psychiatry. 2008; 9(1): 6–23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical